TOP特許意匠商標
商標ウォッチ Twitter
公開日2025-06-04
公報種別公開国際商標公報
国際登録番号1845845
国際登録日2025-01-31
区分第5類(薬剤)
商品役務Pharmaceutical preparations for the prevention and treatment of metabolic and endocrine diseases and disorders; pharmaceutical preparations for the prevention and treatment of medical conditions in the fields of metabolic science and endocrine science.
基礎出願番号98676353
基礎出願日2024-07-31
基礎出願国US
出願人Kailera Therapeutics, Inc.
OCRテキストKAILERA THERAPEUTICS
OCRテキスト2
OCRについて
この商標をJ-PlatPat(特許庁公式サイト)で参照する

関連商標

PHARMEXTRACTA S.p.A.
PHARMEXTRACTA
今日
GlaxoSmithKline Biologicals S.A.
FLUVIXVY
3か月前
Huang, Ke
Huang Lab Smarter Therapeutic Delivery
5か月前
GlaxoSmithKline Biologicals S.A.
REXFLUVA
1か月前
GlaxoSmithKline Biologicals S.A.
AXFLUNA
1か月前
GlaxoSmithKline Biologicals S.A.
BRELLAFLU
1か月前
AstraZeneca AB
ETCAMAH
1か月前
Novo Nordisk A/S
Glemway
3か月前
GlaxoSmithKline Biologicals S.A.
RIXFLUGO
4か月前
Made By Brave Limited
WILD COLLAGEN
6か月前
GlaxoSmithKline Biologicals S.A.
EXFLUNA
4か月前
Novo Nordisk A/S
Anuetake
3か月前
NUTRITIONAL WHOLESOME BLENDS PTY LTD
7か月前
GlaxoSmithKline Biologicals S.A.
FLUVIXGO
3か月前
GlaxoSmithKline Biologicals S.A.
REXFLUGA
27日前
Made By Brave Limited
TRUE OMEGAS+
2か月前
GlaxoSmithKline Biologicals S.A.
INFLENVY
27日前
GlaxoSmithKline Biologicals S.A.
FLUPRIMVA
27日前
GlaxoSmithKline Biologicals S.A.
EXFLUNAY
27日前
GlaxoSmithKline Biologicals S.A.
BREKFLUNA
27日前
GlaxoSmithKline Biologicals S.A.
BEMFLUGO
27日前
GlaxoSmithKline Biologicals S.A.
TRUSESFLU
27日前
Biohaven Therapeutics Ltd.
KREJUTRIA
6か月前
EXELTIS HEALTHCARE, S.L.
_-YNDELLE
1か月前
Aston Group Worldwide Ltd
INESSA
6か月前
Precision Hydration Limited
PRECISION FUEL & HYDRATION
3か月前
Huang, Ke
Huang Lab
5か月前
EXELTIS HEALTHCARE, S.L.
|ノノY
1か月前
Biohaven Therapeutics Ltd.
KAYBELA
6か月前
Made By Brave Limited
TRUE ASHVWAGANDHA
2か月前
Made By Brave Limited
ANCIENT + BRAVE
6か月前
Novo Nordisk A/S
ExtenSIOT
6日前
Beijing Compont Medical Devices Co., Ltd.
ヒロITロロ
4か月前
ZEALAND PHARMA A/S
/EEMO
6か月前
Harbin Fuerjia Technology Co., Ltd.
Volga
6か月前
BETA GIDA SANAYI VE TICARET ANONIM SIRKETI
AirDaby
1か月前
続きを見る